Wedbush Ignites Pyxis Oncology with Bullish Rating — 215% Upside Ahead?
Wedbush rates Pyxis “Outperform” with $6 target vs $1.90. Early cancer drug data promising but risky biotech with funding needs.
/ 2 items
Wedbush rates Pyxis “Outperform” with $6 target vs $1.90. Early cancer drug data promising but risky biotech with funding needs.
Pyxis stock plunged 45% despite positive cancer drug results. Small patient sample, safety issues, and 2026 data timeline worried investors.